Telesis Bio
Telesis Bio is a San Diego-based synthetic biology tools company that sells automated BioXp benchtop workstations, consumable kits, and the Gibson SOLA enzymatic DNA synthesis platform to biopharma companies and academic researchers for in-house DNA and mRNA production.
- Company typePublic
- Founded2018
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Telesis Bio does
Telesis Bio Inc. (formerly Codex DNA; originally SGI-DNA) is a San Diego-based, publicly traded synthetic biology tools company that develops automated instruments and enzymatic chemistry for on-premises synthesis of DNA and mRNA. The company's product portfolio centers on two platforms: the BioXp benchtop workstation family (BioXp 3250 and BioXp 9600), which are push-button, overnight-run instruments paired with application-specific kits for mRNA synthesis, gene synthesis, DNA cloning, cell-free DNA amplification, variant library construction, and NGS library prep; and the Gibson SOLA enzymatic DNA synthesis platform, a digital-to-biological converter deployed on standard liquid-handling automation (including a Beckman Coulter integration) that enables fully enzymatic, on-site, high-fidelity DNA and mRNA production. The underlying Gibson Assembly chemistry, invented by CTO Dr. Daniel G. Gibson, is the industry-standard isothermal DNA assembly method with 6,000+ citations and 300+ patents.
The company monetizes through three streams: capital sales of BioXp instrument hardware, recurring consumable revenue from BioXp kits tied to instrument utilization, and licensing of the Gibson SOLA platform to biopharma R&D core facilities (including disclosed deals with Pfizer in 2022 and Regeneron in 2025). Go-to-market combines direct enterprise sales to biopharma and academic institutions with a global distributor network spanning LATAM, APAC, and EMEA for reagent and kit distribution; orders also flow through the company's myBioXperience secure customer portal. Customer segments are anchored in antibody drug discovery, cell and gene therapy, vaccine development, and digital biology teams — with the company claiming penetration in nearly all Top 25 Biopharma companies alongside premier academic institutions.
Telesis Bio firmographics
Firmographics- Name
- Telesis Bio
- Legal name
- Telesis Bio Inc.
- Website
- https://telesisbio.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Telesis Bio is a San Diego-based synthetic biology tools company that sells automated BioXp benchtop workstations, consumable kits, and the Gibson SOLA enzymatic DNA synthesis platform to biopharma companies and academic researchers for in-house DNA and mRNA production.
- Ownership category
- akta.pro rank
Telesis Bio industry classification
Industry- Product category
- Synthetic Biology Tools & Automated DNA/mRNA Synthesis
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)
Keywords
Where Telesis Bio is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Telesis Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- BioXp Systems (Hardware): Sale of automated benchtop workstations including BioXp 3250 and BioXp 9600 systems. Capital equipment purchase model targeting enterprise customers with R&D facilities.
- BioXp Kits (Consumables): Application-specific consumable kits including mRNA synthesis kits, gene synthesis kits, DNA cloning kits, DNA amplification kits, variant library kits, and NGS library prep kits. Recurring revenue from consumables as instruments are used.
- Gibson SOLA Platform Licensing: Licensing of proprietary Gibson SOLA enzymatic DNA synthesis platform for deployment at customer R&D core facilities. Enables on-premises DNA/mRNA synthesis capabilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | BioXp De novo mRNA Synthesis Kit - 8 and 16 reaction configurations |
| Unit Pricing | Pay-as-you-go | BioXp Select mRNA Synthesis Kit - 8, 16, 24, and 48 reaction configurations |
| Unit Pricing | Pay-as-you-go | BioXp Gene Synthesis Kit - 8 to 96 reaction configurations |
| Unit Pricing | Pay-as-you-go | BioXp De novo DNA Cloning Kit - up to 96 samples per run |
| Unit Pricing | Pay-as-you-go | BioXp Select DNA Cloning Kit - Gibson Assembly and Golden Gate Assembly options |
| Unit Pricing | Pay-as-you-go | BioXp DNA Amplification Kits - various configurations |
| Unit Pricing | Pay-as-you-go | BioXp Error-Corrected Libraries Kits - scanning and combinatorial libraries |
| Unit Pricing | Pay-as-you-go | BioXp NGS Library Prep Kits - Whole Genome and Plasmid Sequencing |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels8 records
Telesis Bio product offering
Product offeringCore offering
Telesis Bio designs, manufactures, and sells automated benchtop synthetic biology workstations (BioXp 3250 and BioXp 9600 systems) together with proprietary enzymatic DNA synthesis technology (Gibson SOLA platform) and application-specific consumable kits for the on-site, overnight synthesis of DNA, mRNA, clones, and variant libraries. The company sells both capital equipment and recurring kits/licensing to biopharma companies, academic research institutions, and emerging biotech startups for therapeutic discovery and vaccine development workflows.
Product overview
Telesis Bio offers a dual-platform portfolio consisting of the BioXp automated benchtop workstations (BioXp 3250 and BioXp 9600 systems) and the Gibson SOLA enzymatic DNA synthesis platform. The BioXp systems serve as the company's original flagship product line, providing fully automated, hands-free synthesis of DNA and mRNA through application-specific BioXp kits including mRNA synthesis, gene synthesis, DNA cloning, cell-free DNA amplification, variant libraries, and NGS library preparation. The newer Gibson SOLA platform represents the company's next-generation enzymatic synthesis technology, designed for deployment on standard liquid-handling automation for scalable in-house DNA and mRNA production. Both platforms leverage proprietary Gibson Assembly chemistry and are supported by the myBioXperience secure ordering portal. The company also provides SARS-CoV-2 synthetic genomes as research products and offers video learning resources for customer education.
Differentiator
Problem solved
Functional benefit
Brands
- BioXp: Automated synthetic biology workstation platform for DNA and mRNA synthesis
- Gibson SOLA
- BioXp 3250 System
- BioXp 9600 System
- BioXp De novo mRNA Synthesis Kit
- BioXp Select mRNA Synthesis Kit
- Gibson Assembly
- Vmax X2
- Digital-to-Biological Converter (DBC)
Products and services
- BioXp 3250 System The award-winning BioXp 3250 is the world's first commercially available benchtop synthetic biology workstation. It synthesizes genes, assembles and amplifies clones, builds DNA variant libraries, and synthesizes synthetic mRNA in a single overnight run (up to 32 fragments per run, 400bp-7000bp fragment length). Targeted at biopharma R&D cores, academic labs, and biotech startups needing hands-free automation.
- BioXp 9600 System The next-generation BioXp 9600 system is a high-throughput synthetic biology workstation enabling accelerated iterative design-build-test discovery cycles. Supports up to 96 fragments per run (300-1,800 bp), 96 clones per run (300-3,600 bp), and 96 libraries per run (300-800 bp). Designed for high-throughput screening workflows in biopharma discovery.
- BioXp mRNA Synthesis Kits BioXp mRNA synthesis kits enable automated 1-step and 2-step synthesis of capped and tailed synthetic mRNA directly from digital sequence or DNA templates. Includes De novo (up to 1.8kb from sequence) and Select (0.4-10kb from template) variants, with CleanCap AG (3'OMe) capping and polyA tail options. Used by vaccine developers, antibody researchers, and cell/gene therapy developers.
- BioXp Gene Synthesis Kit Contains all Gibson Assembly reagents needed to make error-corrected, de novo synthetic gene fragments up to 1.8 kb in length with >200 ng yield per construct. System runtime ~14-16 hours, with 3-5 business day kit shipping turnaround. Available in 8 to 96 reaction configurations for BioXp systems.
- BioXp DNA Cloning Kits Enables automated generation of circular plasmids from user-provided or Telesis Bio-provided fragments or digital sequences. De novo kits synthesize error-corrected fragments up to 7 kb into vectors. Select kits support Gibson Assembly and Golden Gate Assembly methods. Used by researchers building expression constructs for downstream protein or mRNA workflows.
- BioXp Cell-Free DNA Amplification Kit Cell-free amplification on the BioXp eliminates the need for bacterial cultures by allowing users to obtain transfection-scale amplified DNA in less than a day. Uses Rolling Circle Amplification (RCA) technology that bypasses traditional E. coli methods. Sequence-agnostic amplification overcomes copy number and toxicity challenges for large-scale IVT template production.
- BioXp Libraries Kit Variant library synthesis with NNN, NNK, NNS, and IUPAC degenerate codons for protein binding and function optimization. Up to 96 synthesis reactions per run, >200 ng per library construct. Supports scanning and combinatorial libraries with a median error rate of 1 in 5,000 bp. Used for affinity optimization and directed evolution.
- BioXp NGS Library Prep Kit Automated library prep for Illumina sequencers supporting Whole Genome and Plasmid Sequencing workflows. Available in 8, 24, 48, and 96 reaction configurations on both BioXp 3250 and 9600 systems. Streamlines library prep and reduces hands-on time for next-generation sequencing workflows.
- Gibson SOLA Enzymatic DNA Synthesis Platform Revolutionary enzymatic DNA synthesis platform that enables fully-enzymatic, overnight, on-site synthesis of extremely high-fidelity DNA and mRNA, reducing design-to-build timelines from weeks to hours. Uses Short Oligonucleotide Ligation Assembly (SOLA) to build DNA in blocks for higher fidelity and faster workflows. Licensed for deployment on customer R&D core facility standard laboratory automation (Beckman Coulter). Reduces development times by 85% versus outsourcing.
- SARS-CoV-2 Synthetic Genomes Full-length synthetic genomes for SARS-CoV-2 virus variants, including the original strain, D614G mutant, UK variant (B.1.1.7), South Africa variant (B.1.351), Brazil variant (P.1), and a replicon with RLuc reporter. Sold as research reagents to support vaccine and therapeutic discovery.
- Benchtop Reagents High-quality reagent solutions backed by Gibson Assembly technology for customers who prefer to run reactions manually rather than on an automated BioXp workstation. Targeted at labs that have manual workflows but want access to Telesis Bio's proprietary reagent chemistry.
Quantifiable outcome
- Save 7 weeks (90% reduction) over traditional outsourcing methods
- +7 more outcomes
Companies that use Telesis Bio
Customer profileNamed customers8 records
Segments7 records
Ideal customer profiles4 records
Telesis Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Telesis Bio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, strategic, acquisition and research.
- Regeneron PharmaceuticalsflagshipLicensing agreement for Regeneron to deploy Gibson SOLA platform at its R&D core facilities. Enables automated, high-throughput, on-demand gene synthesis in Regeneron's own labs. Platform shown to enable fully-enzymatic, overnight synthesis of high-fidelity DNA and mRNA, reducing design-to-build timelines from weeks to hours.
- Beckman Coulter Life SciencesstrategicCollaboration announced September 2024 to revolutionize DNA and mRNA synthesis. Partnership creates efficient and scalable biofoundry capabilities by integrating Gibson SOLA platform with Beckman Coulter laboratory automation. Gibson SOLA Platform shown installed on Beckman Coulter Life Sciences automation systems.
- PfizerstrategicLicensing deal signed January 2022 for Pfizer to use Telesis Bio technology to help speed up vaccine production. CEO provided facility tour demonstrating technology capabilities for vaccine development.
- Eton BioscienceacquisitionTelesis Bio acquired Eton Bioscience for $13 million in November 2021, combining two San Diego synthetic biology companies. Eton provides therapeutic discovery services including DNA sequencing and biological fragment copying.
- University of Florida, UC Riverside, USDA, Cornell University, AgrosourceresearchCollaboration in federally funded grant to tackle citrus greening disease. Telesis Bio team using Vmax X2 product line for developing therapeutic molecule discovery platform.
Scale indicators14 records
Recent moves8 records
Expansion highlights5 records
Telesis Bio competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights6 records
Customer concentration
Telesis Bio social profiles
Digital presenceTelesis Bio compliance and trust
Trust signalCompliance1 record
Telesis Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Telesis Bio leadership team
Management profileNumber of profiles
Profiles10 records
Telesis Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Telesis Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Telesis Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Telesis Bio
What does Telesis Bio do?
Telesis Bio designs, manufactures, and sells automated benchtop synthetic biology workstations (BioXp 3250 and BioXp 9600 systems) together with proprietary enzymatic DNA synthesis technology (Gibson SOLA platform) and application-specific consumable kits for the on-site, overnight synthesis of DNA, mRNA, clones, and variant libraries. The company sells both capital equipment and recurring kits/licensing to biopharma companies, academic research institutions, and emerging biotech startups for therapeutic discovery and vaccine development workflows.
Is Telesis Bio a public or private company?
Telesis Bio is a public company. It is classified as public and is currently operating.
When was Telesis Bio founded?
Telesis Bio was founded in 2018. It employs 11 to 50 people.
Where is Telesis Bio based?
Telesis Bio is headquartered in San Diego, United States, in the North America region.
How does Telesis Bio make money?
Three revenue lines are on record. BioXp Systems (Hardware) is the primary driver. The others are bioXp Kits (Consumables) and gibson SOLA Platform Licensing.
Does Telesis Bio have an API?
No public API is recorded for Telesis Bio.
What industry is Telesis Bio in?
Telesis Bio's product category is Synthetic Biology Tools & Automated DNA/mRNA Synthesis. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 8731.